{"name":"MSD Pharmaceuticals LLC","slug":"msd-pharmaceuticals-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Antiretroviral/Anti HIV","genericName":"Antiretroviral/Anti HIV","slug":"antiretroviral-anti-hiv","indication":"HIV-1 infection (treatment and prevention)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Golimumab Injection","genericName":"Golimumab Injection","slug":"golimumab-injection","indication":"Rheumatoid arthritis","status":"phase_3"}]}],"pipeline":[{"name":"Antiretroviral/Anti HIV","genericName":"Antiretroviral/Anti HIV","slug":"antiretroviral-anti-hiv","phase":"marketed","mechanism":"Antiretroviral drugs inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells.","indications":["HIV-1 infection (treatment and prevention)"],"catalyst":""},{"name":"Golimumab Injection","genericName":"Golimumab Injection","slug":"golimumab-injection","phase":"phase_3","mechanism":"Golimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Ulcerative colitis","Crohn's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxNdHVKaVdobWdBVVhvNEJ1TEF6TlRvVWk4SUVxaHJrdDcxSXQtVUVnNklPdlhEYTVfbjA4WE9jVmpFeHdZM1R3ektSM0IzTjJLdFdkNmVoWE5ZMzg3anVsMEdiWXBnQ3JoQjl2aUNFSVhsRUxaM0NVUXNhdkZvcXo3M2VpQnJzRWJZM3ppVENrZDNoM0xWYjd1M3NqOWZnSjJhTnVwM2RTZFFsWUN0ampzMnluYUFNdEVLSEN2bFRxLUpNdmw4cElWMXhIbVRmOEduejhTQ1dvR2NJVUlFRmUyVElucFhHanN2dTFZaWVkOXpsRE1ueTRON1poX3pYV0R5MHZJSV9JSGMwd1ZxOTloWXlsM05OZUk0TjJNa21Xa3hmU2JheVE?oc=5","date":"2026-03-25","type":"regulatory","source":"Business Wire","summary":"Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Business Wire","headline":"Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQclRaclNnYnEtN0NfbFZxVmtjZUhZWWQ5NVZ3UTZSRktqbnZRRFgwbHA0cGJLdTg4WTZ2R244TzZOQ0o5SEhzQVBCNGZtSFJ1cXhNRGd0TDFWVUZfXzRSXzJ1TnZMYWRHV09iS2lpX0NtLW45LTQ1cVFISWd4eHB5ZdIBlAFBVV95cUxOTUFPX3dCUFUtLS10bVdPd3Aya041V2ZpNVcxY0UzTGRiS1hRS1RoeC1XaDF0M1E5eVpSb2pQc0hqUk9WNEc1XzNINy00WmpkUWtTaTNGeEVEZ2hXY0Jqd0dPb3BCNTVoQ2FzbTFId3lnVU1oSTJ2NXYyeUZFczZZVE52emRPWk9WWjJfVF9DN2ZNOVVr?oc=5","date":"2026-02-04","type":"pipeline","source":"Chosunbiz","summary":"MSD outlines post-Keytruda growth, keeps Hanmi MASH drug central to pipeline - CHOSUNBIZ - Chosunbiz","headline":"MSD outlines post-Keytruda growth, keeps Hanmi MASH drug central to pipeline - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-09","type":"patent","source":"Business Standard","summary":"Zydus and Formycon ink licensing agreement for biosimilar in US, Canada - Business Standard","headline":"Zydus and Formycon ink licensing agreement for biosimilar in US, Canada","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-04","type":"trial","source":"Medical Dialogues","summary":"CDSCO Flags MSD Pharma's Cancer Drug Trial Over Indian Representation, Control Arm - Medical Dialogues","headline":"CDSCO Flags MSD Pharma's Cancer Drug Trial Over Indian Representation, Control Arm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOSHpBdHlHT3JpVDJMN0RXVlhQYmxBQ3pRSTdQc050cldtQ01aakxFUnVHQ2JBekU0M1M0OTVJVFhfWTFsdkRiX2FnbHJneURXTFBJRDI0TTZ0Wlk0N1lYWDZidElXOVk4UnlZZ0g3aXlPR0l1NnRSVTBqclpTMDZaeHBSMy1RREhXT3JXby1VajU1QlBoejFpY0RVQXpkbUVGYUduX3Qyc25qd2ljckhyYTFVV1VLTDNGWU1Cbk9pMUI1RlFKc2xQc0Iydm9jVWQ5UC1sRmhBUFdMMU81Z3JseA?oc=5","date":"2025-09-11","type":"pipeline","source":"Reuters","summary":"Britain defends investment record as Merck scraps labs over pharma environment - Reuters","headline":"Britain defends investment record as Merck scraps labs over pharma environment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNUZSamhuWGZ0Nmt4VmJuNTNSRTlKV09lY0pHUDBqYWZTeHVmRV9hVmtscDk2NVJCS21rZ3I2TjZ0S05fS1JiTW9jTk94V2ZldDFSeXdwNEVRZEZCUlNuSEVnY2RWMWV5bng3RU9XUS1rVTExQ29VSm9Zc1UyZ3ZzNEdQb2N0dzJ0RFI2aDdWNnV0bXZCOEY4b3ltSVpwLTA3VXh0R0NpSlE2WmdmTWgxZVlWNGZaeVJNcUVlWGdpbjh6X0k?oc=5","date":"2025-09-11","type":"pipeline","source":"The Guardian","summary":"Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit | Pharmaceuticals industry - The Guardian","headline":"Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit | Pharmaceuticals industry","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-09","type":"deal","source":"Business Wire","summary":"Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade -","headline":"Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Main","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPTXhWVWFHYUw3NElVcXhGT091X2lrbC1JcTEtaV9RUV82ZUlVQno0M0w5c2hXWmdOQ3A4ZHUzUGNYSWNOMkh1aDFpek11MFNBWHdXRTBaSGNuT1FydldaeHBON3d0QW5aSVRobGxMWFhsNHR6eUxuRzhsVDd0Q3phSG9UUEh0Vk0wX2dyYVlCekpIdEw3V0FONzF2aFlxQQ?oc=5","date":"2025-03-31","type":"pipeline","source":"The Global Legal Post","summary":"UK court dismisses appeal in Merck v Merck dispute - The Global Legal Post","headline":"UK court dismisses appeal in Merck v Merck dispute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1sS3V1ZEktV1pGS1VvMHY5bHR0Y1FGenlPYS03a09QcWd3bTU4czNrZVBHcGtoaUlweElnRHlQQ0UzMGdkTDlBZHhJaVpiOU40VC1lUVljU1lLaEI4?oc=5","date":"2025-03-18","type":"pipeline","source":"EurekAlert!","summary":"WIN Consortium leading the future of precision cancer medicine - EurekAlert!","headline":"WIN Consortium leading the future of precision cancer medicine - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNbzNpY1VSRWFPaG4ybzNDYXlhZjg0cGQ0NGRfX0p1V0FSSllRSkNkQ0lDQW1PekJqUkNZcTFKSGdTS1lDY0IyU1pSTXNRSDM1UGFQbkVPNDdpVDJpSlg3c0VhZ0MtYnE4Wi1ZTTNUdWxXbTZzT2ZxbklyNEhCbjBRNi1YbGJ5MnlBR1VxMkZ2eUIyd0xp?oc=5","date":"2025-02-12","type":"pipeline","source":"TechCrunch","summary":"US pharma giant Merck backs healthcare marketplace HD in Southeast Asia - TechCrunch","headline":"US pharma giant Merck backs healthcare marketplace HD in Southeast Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPUlNua1pBVTBXQmpkX3E1UnNOd1Z3UEd4N04xNm82d2I1ZmxlZ0tWdkNoQ1ltUWQ3aTNPLW5SckVVTG5fU0gxam92VXBPTmpiTnA4WmN6Wk9iNS1ZVHN1S0t1Rm5HN0N6UXAxb1NsMUtOTTJUNzdLbmFPbE82eXlqZ1VxMXNMb21NVGVhVXVwR1dpakRlUC1Xamlfak85aXlObEdnLVJVQno?oc=5","date":"2025-01-06","type":"deal","source":"fiercepharma.com","summary":"In €500M deal, Merck buys Ireland vaccines plant from CDMO WuXi Biologics - fiercepharma.com","headline":"In €500M deal, Merck buys Ireland vaccines plant from CDMO WuXi Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiOkFVX3lxTE9xUnktMklHVURZci1jbkxlOUlJWXAwd0JFLXItcENtRDJlM3dINVJVZkV0S3BmeFVwcGc?oc=5","date":"2006-03-15","type":"pipeline","source":"Merck.com","summary":"Merck | Home - Merck.com","headline":"Merck | Home","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}